Literature DB >> 20166200

Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs.

Stan L Banks1, Raghotham R Pinninti, Harvinder S Gill, Kalpana S Paudel, Peter A Crooks, Nicole K Brogden, Mark R Prausnitz, Audra L Stinchcomb.   

Abstract

Controlled-release delivery of 6-beta-naltrexol (NTXOL), the major active metabolite of naltrexone, via a transdermal patch is desirable for treatment of alcoholism. Unfortunately, NTXOL does not diffuse across skin at a therapeutic rate. Therefore, the focus of this study was to evaluate microneedle (MN) skin permeation enhancement of NTXOL's hydrochloride salt in hairless guinea pigs. Specifically, these studies were designed to determine the lifetime of MN-created aqueous pore pathways. MN pore lifetime was estimated by pharmacokinetic evaluation, transepidermal water loss (TEWL) and visualization of MN-treated skin pore diameters using light microscopy. A 3.6-fold enhancement in steady-state plasma concentration was observed in vivo with MN treated skin with NTXOL.HCl, as compared to NTXOL base. TEWL measurements and microscopic evaluation of stained MN-treated guinea pig skin indicated the presence of pores, suggesting a feasible nonlipid bilayer pathway for enhanced transdermal delivery. Overall, MN-assisted transdermal delivery appears viable for at least 48 h after MN-application. (c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20166200      PMCID： PMC2862091          DOI： 10.1002/jps.22083

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


  25 in total

1.  Economic cost of alcohol and drug abuse in the United States, 1992: a report.

Authors:  H J Harwood; D Fountain; G Fountain
Journal:  Addiction       Date:  1999-05       Impact factor: 6.526

2.  Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery.

Authors:  John A Mikszta; Jason B Alarcon; John M Brittingham; Diane E Sutter; Ronald J Pettis; Noel G Harvey
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

3.  Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies.

Authors:  Devin V McAllister; Ping M Wang; Shawn P Davis; Jung-Hwan Park; Paul J Canatella; Mark G Allen; Mark R Prausnitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

4.  Transdermal delivery of desmopressin using a coated microneedle array patch system.

Authors:  Michel Cormier; Bonny Johnson; Mahmoud Ameri; Kofi Nyam; Luz Libiran; Dee Dee Zhang; Pete Daddona
Journal:  J Control Release       Date:  2004-07-07       Impact factor: 9.776

5.  Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force.

Authors:  Shawn P Davis; Benjamin J Landis; Zachary H Adams; Mark G Allen; Mark R Prausnitz
Journal:  J Biomech       Date:  2004-08       Impact factor: 2.712

6.  Burn wound evaporation--measurement of body fluid loss by probe evaporimeter and weight change.

Authors:  J C Ferguson; C J Martin; C Rayner
Journal:  Clin Phys Physiol Meas       Date:  1991-05

7.  Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.

Authors:  M C Meyer; A B Straughn; M W Lo; W L Schary; C C Whitney
Journal:  J Clin Psychiatry       Date:  1984-09       Impact factor: 4.384

8.  Metabolism and disposition of naltrexone in man after oral and intravenous administration.

Authors:  M E Wall; D R Brine; M Perez-Reyes
Journal:  Drug Metab Dispos       Date:  1981 Jul-Aug       Impact factor: 3.922

9.  Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinan.

Authors:  B R de Costa; M J Iadarola; R B Rothman; K F Berman; C George; A H Newman; A Mahboubi; A E Jacobson; K C Rice
Journal:  J Med Chem       Date:  1992-07-24       Impact factor: 7.446

10.  Transdermal delivery of insulin using microneedles in vivo.

Authors:  Wijaya Martanto; Shawn P Davis; Nicholas R Holiday; Jenny Wang; Harvinder S Gill; Mark R Prausnitz
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200
View more
  22 in total

1.  Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery.

Authors:  Thirupathi Reddy Yerramreddy; Mikolaj Milewski; Narsimha Reddy Penthala; Audra L Stinchcomb; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-18       Impact factor: 2.823

2.  Recovery of skin barrier after stratum corneum removal by microdermabrasion.

Authors:  Samantha Andrews; Jeong Woo Lee; Mark Prausnitz
Journal:  AAPS PharmSciTech       Date:  2011-10-19       Impact factor: 3.246

3.  Paediatricians' opinions of microneedle-mediated monitoring: a key stage in the translation of microneedle technology from laboratory into clinical practice.

Authors:  Karen Mooney; James C McElnay; Ryan F Donnelly
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 4.617

4.  In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin.

Authors:  Mikolaj Milewski; Thirupathi Reddy Yerramreddy; Priyanka Ghosh; Peter A Crooks; Audra L Stinchcomb
Journal:  J Control Release       Date:  2010-06-04       Impact factor: 9.776

5.  Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in yucatan minipig: in vitro-in vivo correlation.

Authors:  Mikolaj Milewski; Kalpana S Paudel; Nicole K Brogden; Priyanka Ghosh; Stan L Banks; Dana C Hammell; Audra L Stinchcomb
Journal:  Mol Pharm       Date:  2013-09-23       Impact factor: 4.939

6.  Kinetics of skin resealing after insertion of microneedles in human subjects.

Authors:  Jyoti Gupta; Harvinder S Gill; Samantha N Andrews; Mark R Prausnitz
Journal:  J Control Release       Date:  2011-05-26       Impact factor: 9.776

Review 7.  Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin.

Authors:  Mikolaj Milewski; Nicole K Brogden; Audra L Stinchcomb
Journal:  Expert Opin Drug Deliv       Date:  2010-05       Impact factor: 6.648

8.  Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery.

Authors:  Joshua A Eldridge; Mikolaj Milewski; Audra L Stinchcomb; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2014-10-02       Impact factor: 2.823

Review 9.  Targeting the skin for microneedle delivery of influenza vaccine.

Authors:  Dimitrios G Koutsonanos; Richard W Compans; Ioanna Skountzou
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

10.  Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery.

Authors:  Priyanka Ghosh; Nicole K Brogden; Audra L Stinchcomb
Journal:  Mol Pharm       Date:  2013-05-13       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.